Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer — sNSCLC  

Advanced Squamous Non-small Cell Lung Cancer Clinical Trial

Official title: Recombinant Anti-EGFR Monoclonal Antibody（SCT200） in Patients With Advanced Squamous Non-small Cell Lung Cancer : a Phase Ib, Open-label, Multicenter Study

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced squamous non-small cell lung cancer treated after failure of Two chemotherapy regimens (including Platinum-based drugs).

Clinical Trial Description

This open label multicenter phase Ib study is designed to evaluate Objective Response Rate (ORR) in Squamous non-small cell Lung cancer treated with anti-EGFR monoclonal antibody SCT200. ;

Related Conditions & MeSH terms

• Advanced Squamous Non-small Cell Lung Cancer
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms

• NCT number: NCT03808701
• Study type: Interventional
• Source: Sinocelltech Ltd.
• Contact: CHENG YING, MD
• Phone: 0431-85872688
• Email: chengying@csco.org.cn
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: March 2019
• Completion date: December 2019